The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (interstitial lung disease/ILD)
Publications
Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir.
Journal of pharmaceutical health care and sciences 2020;6;6 — 2020 — 6
VIEKIRA PAK associated drug-induced interstitial lung disease: Case series with systematic review of literature.
Clinical and molecular hepatology 2019 Jun;25;218-222 — 2019 Jun — 218-222
A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir.
Case reports in gastroenterology 2017 May-Aug;11;369-376 — 2017 May-Aug — 369-376
Kawaoka T, Imamura M, Morio K, Nakamura Y, Tsuge M, Nelson Hayes C, Kawakami Y, Aikata H, Ochi H, Ishiyama K, Ohdan H, Chayama K
Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.
Clinical journal of gastroenterology 2017 Apr;10;179-184 — 2017 Apr — 179-184
Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient.
Mayo Clinic proceedings 2015 Sep;90;1294-7 — 2015 Sep — 1294-7